Brain Biotech und der 128-Millionen-Euro-Deal - der "Big Deal" hat sein "Kleingedrucktes"
Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…
56,550€
-0,54%
Echtzeit-Aktienkurs Royalty Pharma PLC
Bid:
Ask:
Nachrichten zur Royalty Pharma PLC Aktie
EQS-Adhoc: BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab (deutsch)
BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
…
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
…
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…
Royalty Pharma plc (NASDAQ:RPRX) Stocks Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…
Earnings call: Royalty Pharma reports robust growth and strategic acquisitions By Investing.com
Earnings call: Royalty Pharma reports robust growth and strategic acquisitions…
Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
…
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will…
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…